Phase I study of docetaxel plus S-1 combination chemotherapy for recurrent non-small cell lung cancer

S-1 is a novel oral fluorouracil prodrug that plays a role in non-small cell lung cancer (NSCLC). Docetaxel (DTX) is one of the standard agents for relapsed NSCLC. We performed a phase I study of DTX plus S-1 combination therapy as second-line treatment for NSCLC to determine the maximum tolerated d...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: FUJITAKA, KAZUNORI, HATTORI, NOBORU, SENOO, TADASHI, IWAMOTO, HIROSHI, OHSHIMO, SHINICHIRO, KANEHARA, MASASHI, ISHIKAWA, NOBUHISA, HARUTA, YOSHINORI, MURAI, HIROSHI, KOHNO, NOBUOKI
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: D.A. Spandidos 2011
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3412446/
https://ncbi.nlm.nih.gov/pubmed/22870147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2010.218
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller